Xenetic: Skyrockets as partner reports positive data from anemia drug trial
09/12/2020 16:03
** Shares of biopharma co XBIO.O surge 300% to $4.32 -
their highest in over one year
** XBIO is biggest pct gainer and among most heavily traded
stocks across U.S. exchanges
** Co says its partner, PJSC Pharmsynthez, reported positive
data from its pivotal late-stage clinical study testing its drug
candidate Epolong for anemia in patients with chronic kidney
disease urn:newsml:reuters.com:*:nACStkQ1ma
** Says study results indicated Epolong was non-inferior to
Amgen Inc's AMGN.O drug Aranesp with respect to main and
secondary goals
** Proportion of patients who achieved target hemoglobin
range during evaluation period was 74% in Epolong group vs 52%
in Aranesp group - Co
** Up to Tuesday's close, stock had fallen 25% YTD
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))